WebFilings | EDGAR view
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 
Washington, DC 20549
_____________________________________________________________________
 
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 
______________________________________________________________________
 
Date of Report (Date of earliest event reported): January 3, 2011
 
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in charter)
 
DELAWARE
1-11083
04-2695240
(State or other
(Commission
(IRS employer
jurisdiction of
file number)
identification no.)
incorporation)
 
 
 
One Boston Scientific Place, Natick, Massachusetts
01760-1537
(Address of principal executive offices)
(Zip code)
 
Registrant's telephone number, including area code:   (508) 650-8000
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 

 

ITEM 8.01.     OTHER EVENTS.
 
On January 3, 2011, the Company announced that it has completed the sale of its Neurovascular business to Stryker Corporation, following the signing of a definitive agreement announced on October 28, 2010.
 
In addition, the Company announced the prepayment on December 31, 2010 of all $600 million of its 6.00 percent senior notes due June 15, 2011, using cash on hand.
 
A copy of the Company's press release announcing both of these matters is included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
 
 
ITEM 9.01. 
FINANCIAL STATEMENTS AND EXHIBITS.
 
 
(d) Exhibits
 
 
 
Exhibit  No.
Description
 
 
99.1 
Press Release issued by Boston Scientific Corporation dated January 3, 2011.
 
 
 
 
 

 

 

 
SIGNATURE
 
 
Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
                        
                                
Date: January 3, 2011
BOSTON SCIENTIFIC CORPORATION
 
 
 
 
 
 
By:
/s/ Vance R. Brown
 
 
 
Vance R. Brown
 
 
 
Vice President and Chief Corporate Counsel
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 

INDEX TO EXHIBITS
 
Exhibit  No.
Description
 
 
99.1 
Press Release issued by Boston Scientific Corporation dated January 3, 2011.